AUS
NZ
UK
CA
USA
IND
Highlights
- SHL shares trading below 5-year average valuation
- Healthcare sector offers stable long-term potential
- Ethical and defensive traits boost sector appeal
Sonic Healthcare Ltd (ASX:SHL) has long stood as a significant player in the global healthcare sector. Listed since 1987, the company operates one of the largest pathology and diagnostic services networks across Australia, New Zealand, Europe, and North America. Despite a 3.0% dip in the SHL share price since the start of 2025, the broader fundamentals and global trends may support interest in this healthcare stock.
The company’s diversified services range from laboratory medicine, diagnostic imaging, radiology, and general practice to corporate medical services. Its operations are grounded in a model focused on medical excellence and patient outcomes, which positions it well in a sector increasingly influenced by ethical investing principles.
In terms of sector-wide trends, the S&P/ASX200 Healthcare Index (ASX:XHJ) has underperformed the broader market with a return of just 0.17% annually over the last five years, compared to 7.14% for the ASX200. However, this slower pace masks some of the fundamental strengths of healthcare as a defensive sector. Healthcare spending is typically essential, making revenues more resilient even in downturns. During past economic challenges, including the GFC, healthcare outperformed due to this ‘sticky revenue’ nature.
Long-term growth prospects also shine brightly. Global healthcare spending is forecast to grow, with US healthcare alone expected to reach US$819 billion by 2027 at a 7% annual growth rate. Sub-sectors such as healthcare IT and SaaS-based platforms are set to grow even faster, exceeding 15% annual growth through 2030. This signals not just stability, but innovation-led growth potential.
For those tracking opportunities in ASX dividend stocks, Sonic Healthcare's role in essential services could make it a part of income-focused strategies. As healthcare companies often maintain consistent earnings, they may also offer dependable dividend streams. For more dividend insights, refer to ASX dividend stocks.
Valuation-wise, Sonic Healthcare’s price-to-sales (P/S) ratio is currently at 1.42x, which is below its five-year average of 1.94x. This could indicate that the share price hasn't kept pace with revenue growth, potentially opening a window of opportunity for long-term investors.
Given the rising emphasis on sustainable investing, the appeal of healthcare as an ethical and defensive sector remains strong. In a climate where more investors are allocating funds to ethical options, companies like Sonic Healthcare could benefit from increased attention.
Additionally, those monitoring broader market trends may wish to track the All Ordinaries index to gauge overall investor sentiment across Australian equities.
Sonic Healthcare (SHL), with its global footprint, consistent growth, and ethical focus, may continue to attract interest as a potential long-term player in the ASX200 healthcare space.
